TACE+AC provided a clinical benefit for OS in these subgroups as follows: age less than 65 years, ECOG PS score of 1, Child–Pugh classification of B, AFP greater than or equal to 200 ng/ml, male, liver cirrhosis, and hepatitis B infected. The gene discussed is AFP; the disease is hepatitis B virus infection.